JAC Advance Access originally published online on September 29, 2005
Journal of Antimicrobial Chemotherapy 2005 56(6):1081-1086; doi:10.1093/jac/dki356
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy
Laboratory of Immunobiología-Molecular, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Received 5 July 2005; returned 15 August 2005; revised 8 September 2005; accepted 9 September 2005
* Corresponding author. Tel: +34-91-586-8565; Fax: +34-91-586-8018; E-mail: mmunoz.hgugm{at}salud.madrid.org
Background: Lopinavir/ritonavir is a protease inhibitor (PI) that has shown great effectiveness as salvage therapy in PI-experienced HIV-infected children.
Objectives: To study whether mutations in the HIV-1 protease gene can reliably predict virological responses to salvage therapy with lopinavir/ritonavir in HIV-infected children.
Patients and methods: We carried out a prospective study in 56 HIV-infected children. PI-associated resistance mutations were determined by genotypic testing and were scored according to the IAS-USA guidelines 2005.
Results: Children with a ‘lopinavir mutation score’ (LMS) 
6 had a negative association for achieving viral load (VL) control [undetectable viral load (uVL) 
400 copies/mL] and maintaining uVL for at least 6 months. Moreover, children with protease-associated mutations (PRAMs) 2 had a negative association for achieving VL control but not for maintaining uVL for at least 6 months. The relative proportion (RP) to uVL was 0.32 (CI95%: 0.16; 0.33; P = 0.002) in children with I54V (46% of total) and 0.48 (CI95%: 0.24; 0.97; P = 0.041) in children with V82A/F (52% of total). Children with I54V and V82A/F had higher prevalence of lopinavir-associated resistance mutations and showed RP of 0.36 (CI95%: 0.17; 0.76; P = 0.007) for achieving uVL.
Conclusions: LMS and PRAMs in HIV-infected children were associated with virological failure in pre-treated HIV-infected children on salvage therapy with lopinavir/ritonavir. Moreover, I54V and V82A/F led to the poorest virological response.
Keywords: HIV-1 , viral load , salvage therapy , resistance
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Murphy, H. France, H. Sunpath, M. L. Gordon, V. C. Marconi, D. R. Kuritzkes, and K. McIntosh Development of Dual-class Antiretroviral Drug Resistance in a Child Coinfected with HIV and Tuberculosis: A Case Report from KwaZulu-Natal, South Africa J Trop Pediatr, February 1, 2009; 55(1): 60 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Larru, S. Resino, J. M. Bellon, M. I. de Jose, C. Fortuny, M. L. Navarro, M. D. Gurbindo, J. T. Ramos, P. Soler Palacin, J. A. Leon, et al. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children J. Antimicrob. Chemother., January 1, 2008; 61(1): 183 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Resino, J. M. Bellon, M. A. Munoz-Fernandez, and on behalf of the Spanish Group of HIV Infection Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency J. Antimicrob. Chemother., March 1, 2006; 57(3): 579 - 582. [Full Text] [PDF]
|
|